

# Giuseppe Lopalco

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9347951/publications.pdf>

Version: 2024-02-01

186  
papers

3,755  
citations

126708

33  
h-index

189595

50  
g-index

189  
all docs

189  
docs citations

189  
times ranked

3488  
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin 1 $\pm$ : a comprehensive review on the role of IL-1 $\pm$ in the pathogenesis and treatment of autoimmune and inflammatory diseases. <i>Autoimmunity Reviews</i> , 2021, 20, 102763.	2.5	140
2	Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2017, 36, 191-197.	1.0	115
3	Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International) Tj ETQq1 1 0.784314 rgBT /Overlo 956-964.	0.8	98
4	Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study. <i>Clinical Rheumatology</i> , 2016, 35, 1281-1286.	1.0	95
5	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2017, 8, 369.	1.6	89
6	Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2017, 36, 183-189.	1.0	84
7	Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. <i>Hepatology</i> , 2015, 62, 40-46.	3.6	82
8	Interleukin-1 as a Common Denominator from Autoinflammatory to Autoimmune Disorders: Premises, Perils, and Perspectives. <i>Mediators of Inflammation</i> , 2015, 2015, 1-21.	1.4	79
9	Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease. <i>Autoimmunity Reviews</i> , 2015, 14, 1-9.	2.5	79
10	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 295-306.	2.9	78
11	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2016, 7, 380.	1.6	72
12	A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome. <i>Clinical Rheumatology</i> , 2017, 36, 463-468.	1.0	64
13	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2018, 37, 2233-2240.	1.0	64
14	Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors. <i>Journal of Clinical Medicine</i> , 2018, 7, 504.	1.0	61
15	Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1898.	1.8	60
16	Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome. <i>Clinical Rheumatology</i> , 2014, 33, 1197-1207.	1.0	58
17	Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. <i>Clinical Rheumatology</i> , 2019, 38, 407-415.	1.0	56
18	Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis. <i>Autoimmunity Reviews</i> , 2015, 14, 90-97.	2.5	55

#	ARTICLE	IF	CITATIONS
19	Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy. <i>Autoimmunity Reviews</i> , 2016, 15, 447-450.	2.5	54
20	Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2017, 36, 451-455.	1.0	52
21	Proinflammatory Cytokines and Antiskin Autoantibodies in Patients With Inherited Epidermolysis Bullosa. <i>Medicine (United States)</i> , 2015, 94, e1528.	0.4	51
22	Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab. <i>Clinical Rheumatology</i> , 2015, 34, 1141-1143.	1.0	51
23	Cytokine Signatures in Mucocutaneous and Ocular Behçet's Disease. <i>Frontiers in Immunology</i> , 2017, 8, 200.	2.2	50
24	Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. <i>Internal and Emergency Medicine</i> , 2018, 13, 475-489.	1.0	48
25	The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 298-304.	1.0	46
26	Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study. <i>British Journal of Ophthalmology</i> , 2018, 102, 637-641.	2.1	44
27	Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCl) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13013.	1.7	42
28	Basic Characteristics of Adults with Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenopathy Syndrome in Comparison with the Typical Pediatric Expression of Disease. <i>Mediators of Inflammation</i> , 2015, 2015, 1-11.	1.4	41
29	Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet's phenotype: a multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1098-1104.	0.5	39
30	Certolizumab Pegol treatment in Behçet's disease with different organ involvement: A multicenter retrospective observational study. <i>Modern Rheumatology</i> , 2017, 27, 1031-1035.	0.9	38
31	The right place of interleukin-1 inhibitors in the treatment of Behçet's syndrome: a systematic review. <i>Rheumatology International</i> , 2019, 39, 971-990.	1.5	38
32	The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy. <i>Clinical Rheumatology</i> , 2015, 34, 17-28.	1.0	37
33	Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 34-39.	1.0	37
34	New therapeutic solutions for Behçet's syndrome. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 827-840.	1.9	36
35	Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease. <i>Clinical Rheumatology</i> , 2017, 36, 2063-2069.	1.0	36
36	Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. <i>Clinical Rheumatology</i> , 2018, 37, 2805-2809.	1.0	35

#	ARTICLE	IF	CITATIONS
37	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019, 10, 296.	1.6	35
38	IL-6 blockade in the management of non-infectious uveitis. <i>Clinical Rheumatology</i> , 2017, 36, 1459-1469.	1.0	33
39	COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence. <i>Rheumatology International</i> , 2020, 40, 827-828.	1.5	33
40	Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet's Disease. <i>Medicine (United States)</i> , 2015, 94, e1858.	0.4	31
41	Canakinumab efficacy in refractory adult-onset PFAPA syndrome. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1050-1051.	0.9	31
42	The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 265-274.	2.3	31
43	Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment. <i>Mediators of Inflammation</i> , 2018, 2018, 1-7.	1.4	30
44	Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases. <i>Current Cardiology Reports</i> , 2018, 20, 61.	1.3	29
45	Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. <i>Clinical Rheumatology</i> , 2019, 38, 63-70.	1.0	29
46	The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 187-195.	0.4	29
47	Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. <i>Clinical Rheumatology</i> , 2016, 35, 2631-2638.	1.0	28
48	PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists. <i>Clinical Rheumatology</i> , 2016, 35, 501-505.	1.0	28
49	Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study. <i>Mediators of Inflammation</i> , 2019, 2019, 1-8.	1.4	27
50	Interleukin-1 Inhibition in Behçet's disease. <i>Israel Medical Association Journal</i> , 2016, 18, 171-6.	0.1	26
51	Untangling the Web of Systemic Autoinflammatory Diseases. <i>Mediators of Inflammation</i> , 2014, 2014, 1-15.	1.4	25
52	Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 918.	1.6	25
53	Pain Processing and Vegetative Dysfunction in Fibromyalgia: A Study by Sympathetic Skin Response and Laser Evoked Potentials. <i>Pain Research and Treatment</i> , 2017, 2017, 1-12.	1.7	24
54	Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behçet's disease. <i>Immunology Letters</i> , 2018, 201, 38-44.	1.1	24

#	ARTICLE	IF	CITATIONS
55	Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis. <i>Rheumatology</i> , 2020, 59, 1599-1606.	0.9	24
56	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF- $\alpha$ Receptor-Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. <i>Mediators of Inflammation</i> , 2020, 2020, 1-12.	1.4	24
57	A convolutional neural network with transfer learning for automatic discrimination between low and high-grade synovitis: a pilot study. <i>Internal and Emergency Medicine</i> , 2021, 16, 1457-1465.	1.0	23
58	Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 531-8.	0.4	23
59	Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives. <i>Mediators of Inflammation</i> , 2015, 2015, 1-10.	1.4	22
60	Heterogeneous clinical spectrum of interstitial lung disease in patients with anti-EJ anti-synthetase syndrome: a case series. <i>Clinical Rheumatology</i> , 2016, 35, 2363-2367.	1.0	22
61	Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 103-108.	0.9	22
62	Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab. <i>Clinical Rheumatology</i> , 2018, 37, 1715-1720.	1.0	21
63	Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet's disease. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1736-1737.	0.5	21
64	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , 2020, 7, 42.	1.2	21
65	Demographic, clinical and therapeutic findings in a monocentric cohort of adult patients with suspected PFAPA syndrome. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 77-81.	0.4	21
66	Non-canonical manifestations of familial Mediterranean fever: a changing paradigm. <i>Clinical Rheumatology</i> , 2015, 34, 1503-1511.	1.0	20
67	Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. <i>Clinical Rheumatology</i> , 2015, 34, 807-809.	1.0	20
68	Development and preliminary validation of the Behçet's syndrome Overall Damage Index (BODI). <i>RMD Open</i> , 2020, 6, e001192.	1.8	20
69	Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis. <i>Mediators of Inflammation</i> , 2020, 2020, 1-5.	1.4	20
70	Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings. <i>Journal of Rheumatology</i> , 2016, 43, 911-917.	1.0	19
71	The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors. <i>Frontiers in Pharmacology</i> , 2019, 10, 1468.	1.6	19
72	Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome. <i>Inflammopharmacology</i> , 2020, 28, 711-718.	1.9	19

#	ARTICLE	IF	CITATIONS
73	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss syndrome). <i>European Respiratory Journal</i> , 2021, 57, 2004158.	3.1	19
74	Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors. <i>RMD Open</i> , 2022, 8, e001847.	1.8	19
75	Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 680-683.	0.4	19
76	Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Stillâ€™s Disease. <i>Mediators of Inflammation</i> , 2020, 2020, 1-7.	1.4	18
77	Interleukin-1: Ariadne's Thread in Autoinflammatory and Autoimmune Disorders. <i>Israel Medical Association Journal</i> , 2015, 17, 93-7.	0.1	18
78	Efficacy and Safety of Intravenous Immunoglobulin Treatment in Refractory Behcet's Disease with Different Organ Involvement: A Case Series. <i>Israel Medical Association Journal</i> , 2016, 18, 238-42.	0.1	18
79	Update on the Medical Management of Gastrointestinal Behçetâ€™s Disease. <i>Mediators of Inflammation</i> , 2017, 2017, 1-11.	1.4	16
80	The protean ocular involvement in monogenic autoinflammatory diseases: state of the art. <i>Clinical Rheumatology</i> , 2015, 34, 1171-1180.	1.0	15
81	Biological therapies for the treatment of Behçetâ€™s disease-related uveitis beyond TNF-alpha blockade: a narrative review. <i>Rheumatology International</i> , 2018, 38, 25-35.	1.5	15
82	A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 1309-1317.	1.0	15
83	Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis. <i>Frontiers in Pharmacology</i> , 2018, 9, 1526.	1.6	15
84	New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy. <i>Mediators of Inflammation</i> , 2020, 2020, 1-6.	1.4	15
85	Epidemiological profile of non-infectious uveitis from the rheumatologist's perspective: a survey from two tertiary referral centres in Italy. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 68-73.	0.4	15
86	Serum amyloid-A in Behçetâ€™s disease. <i>Clinical Rheumatology</i> , 2014, 33, 1165-1167.	1.0	14
87	Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102152.	0.9	14
88	Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. <i>Joint Bone Spine</i> , 2021, 88, 105062.	0.8	14
89	A Machine Learning Approach for Predicting Sustained Remission in Rheumatoid Arthritis Patients on Biologic Agents. <i>Journal of Clinical Rheumatology</i> , 2021, Publish Ahead of Print, .	0.5	14
90	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Uveitis. <i>Ophthalmology and Therapy</i> , 2022, 11, 899-911.	1.0	14

#	ARTICLE	IF	CITATIONS
91	Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behçet's disease. <i>Internal and Emergency Medicine</i> , 2019, 14, 719-722.	1.0	13
92	Behçet's syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics. <i>Internal and Emergency Medicine</i> , 2020, 15, 1031-1039.	1.0	13
93	Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory Behçet disease uveitis and concomitant bladder papillary carcinoma. <i>Internal Medicine Journal</i> , 2017, 47, 1086-1088.	0.5	11
94	Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes serum levels in patients with rheumatoid arthritis following treatment with different biological drugs. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 424-9.	0.4	11
95	Systemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internists' lens. <i>Internal and Emergency Medicine</i> , 2016, 11, 781-791.	1.0	10
96	Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 19-23.	1.0	10
97	Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 762-767.	0.4	10
98	Management of Small Vessel Vasculitides. <i>Current Rheumatology Reports</i> , 2016, 18, 36.	2.1	9
99	Rapid desensitization to anakinra-related delayed reaction: Need for a standardized protocol. <i>Journal of Dermatology</i> , 2017, 44, 981-982.	0.6	9
100	Auditory involvement in Behçet's disease: relationship with demographic, clinical, and therapeutic characteristics. <i>Clinical Rheumatology</i> , 2017, 36, 445-449.	1.0	9
101	Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus. <i>Rheumatology</i> , 2020, 59, 1188-1188.	0.9	9
102	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis. <i>Ophthalmology and Therapy</i> , 2022, 11, 887-897.	1.0	9
103	Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 353.	1.1	9
104	Development and Implementation of the AIDA International Registry for Patients With Still's Disease. <i>Frontiers in Medicine</i> , 2022, 9, 878797.	1.2	9
105	Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering. <i>Frontiers in Immunology</i> , 2022, 13, 860877.	2.2	9
106	Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1769-1772.	0.5	9
107	Clinical profile and evolution of patients with juvenile-onset Behçet's syndrome over a 25-year period: insights from the AIDA network. <i>Internal and Emergency Medicine</i> , 2021, 16, 2163-2171.	1.0	8
108	Efficacy of anti-tumour necrosis factor- $\alpha$ monoclonal antibodies in patients with non-infectious anterior uveitis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 301-305.	0.4	8



#	ARTICLE	IF	CITATIONS
109	The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 187-195.	0.4	8
110	Discordance between patient and physician global assessment of disease activity in Behçet's syndrome: a multicenter study cohort. <i>Arthritis Research and Therapy</i> , 2020, 22, 278.	1.6	7
111	Anakinra long-term efficacy and safety in the management of Schnitzler's syndrome and latent tuberculosis infection. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 353.	0.4	7
112	Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 93-97.	0.4	7
113	Intravitreal Dexamethasone Implant as an Adjunct Weapon for Severe and Refractory Uveitis in Behçet's Disease. <i>Israel Medical Association Journal</i> , 2017, 19, 415-419.	0.1	7
114	Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers. <i>Israel Medical Association Journal</i> , 2018, 20, 438-441.	0.1	7
115	Different switching rate of anti-TNF drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life. <i>Joint Bone Spine</i> , 2014, 81, 458-459.	0.8	6
116	Paradoxical Pustular Psoriasis in a Patient With Psoriatic Arthritis on Secukinumab Treatment. <i>Journal of Clinical Rheumatology</i> , 2020, 26, e208-e209.	0.5	6
117	Safety of systemic treatments for Behçet's syndrome. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1269-1301.	1.0	6
118	Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast. <i>Clinical and Experimental Immunology</i> , 2020, 201, 200-204.	1.1	6
119	Predictors of long-term clinical remission in rheumatoid arthritis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13363.	1.7	6
120	Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome: Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network. <i>Frontiers in Medicine</i> , 2021, 8, 668173.	1.2	6
121	Adult-onset tumour necrosis factor receptor-associated periodic syndrome presenting with refractory chronic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S171-2.	0.4	6
122	Empowering Patients in the Therapeutic Decision-Making Process: A Glance Into Behçet's Syndrome. <i>Frontiers in Medicine</i> , 2021, 8, 769870.	1.2	6
123	Successful treatment with anakinra of refractory pericarditis in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 227-227.	0.4	6
124	A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
125	Retinal Vessels Thrombosis as Onset Manifestation of Systemic Sclerosis: 3 Clinical Cases. <i>Journal of Rheumatology</i> , 2014, 41, 2495-2496.	1.0	5
126	Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M variant. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 473-475.	0.9	5



#	ARTICLE	IF	CITATIONS
127	Ustekinumab efficacy and safety in mucocutaneous multi-refractory Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 108, 130-131.	0.4	5
128	A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy. <i>Reumatismo</i> , 2014, 65, 298.	0.4	4
129	Tomographic regression of pulmonary rheumatoid nodules under baricitinib therapy. <i>Rheumatology</i> , 2019, 58, 440-440.	0.9	4
130	Influence of changes in cholesterol levels and disease activity on the 10 years cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e104-e104.	0.5	4
131	Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry. <i>Rheumatology</i> , 2021, 60, 5705-5712.	0.9	4
132	Anakinra effectiveness in refractory polyserositis: An Italian multicenter study. <i>Joint Bone Spine</i> , 2022, 89, 105299.	0.8	4
133	Effectiveness of TNF-Î± blockade in the treatment of refractory non-infectious scleritis: a multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1138-1144.	0.4	4
134	Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Behçet's disease. <i>Pediatric Rheumatology</i> , 2015, 13, .	0.9	3
135	Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. <i>Archives of Rheumatology</i> , 2020, 35, 163-169.	0.3	3
136	Histopathologic Features of Fibrotic Knee Synovitis in a Young Adult With Seronegative Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e73-e74.	0.5	3
137	OPO148&#x2013;MEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A RETROSPECTIVE REAL-WORLD EUROPEAN STUDY ON 142 PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 94-95.	0.5	3
138	Correlation of Serum Amyloid-A Levels, Clinical Manifestations, Treatment, and Disease Activity in Patients with Behçet's Disease. <i>Israel Medical Association Journal</i> , 2018, 20, 517-521.	0.1	3
139	Retention rate of IL-1 inhibitors in Schnitzler's syndrome. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	3
140	Refractory knee giant cell tumor of the synovial membrane treated with intra-articular injection of Infliximab: a case series and review of the literature. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 908-912.	0.9	2
141	Role of nerve growth factor and tropomyosin receptor kinase A in the pathogenesis of osteoarthritis. Might nerve growth factor be the link intertwining obesity and osteoarthritis?. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e70-e70.	0.5	2
142	High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry. <i>Clinical Rheumatology</i> , 2021, 40, 3659-3665.	1.0	2
143	Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection. <i>Internal and Emergency Medicine</i> , 2022, 17, 475-480.	1.0	2
144	Complete Hydatidiform Mole Mimicking Sacroiliitis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e122-e122.	0.5	2

#	ARTICLE	IF	CITATIONS
145	Long-term tocilizumab efficacy in a patient with psoriatic arthritis and AA amyloidosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 170-171.	0.4	2
146	Coexistence of axial spondyloarthritis and thromboangiitis obliterans in a young woman. <i>Reumatismo</i> , 2015, 67, 17-20.	0.4	1
147	SAT0216â€¦Chest Ultrasound Signs of Interstitial Lung Disease in Systemic Sclerosis Patients: A Comparison between High Resolution Chest Computed Tomography Findings. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 747.1-747.	0.5	1
148	AB0037â€¦Serum cytokine signature in mucocutaneous and ocular behçet's disease. , 2017, , .		1
149	AB0709â€¦Switching from originator infliximab to biosimilar infliximab: efficacy and safety in a cohort of patients with established behçet's disease. , 2018, , .		1
150	287.â€¦TOCILIZUMAB TREATMENT FOR LARGE VESSELS VASCULITIS: REAL LIFE PRELIMINARY EXPERIENCES. <i>Rheumatology</i> , 2019, 58, .	0.9	1
151	AB0608â€¦TOCILIZUMAB TREATMENT FOR LARGE VESSELS VASCULITIS: REAL LIFE PRELIMINARY EXPERIENCES. , 2019, , .		1
152	Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110371.	1.2	1
153	OP0093â€¦RETENTION RATE OF IL-1 INHIBITORS IN PATIENTS WITH SCHNITZLERâ€™S SYNDROME. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 51-52.	0.5	1
154	Successful treatment with anakinra of refractory pericarditis in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 227.	0.4	1
155	AB0065â€¦Possible Interplay Between Serum Amyloid-A and Pro-Inflammatory Cytokines Into the Pathogenesis of Behçet's Disease. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 912.2-912.	0.5	0
156	AB0452â€¦Changes in Lipoproteins Associated with Tocilizumab Treatment Do not Influence the Atherogenic Index of Plasma of Rheumatoid Arthritis Patients: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1046.3-1047.	0.5	0
157	SAT0384â€¦Long-Term Safety of Anti-Tnf Agents in Patients with Spondyloarthritis and Potential Occult HBV: An Observational Multicenter Study on 131 Patients. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 807.1-807.	0.5	0
158	THU0540â€¦Efficacy and safety of adalimumab in behçet's disease related uveitis: a multicenter retrospective observational study. , 2017, , .		0
159	AB1160â€¦Epidemiology and clinical presentation of ocular involvement in a population of 278 patients with non infectious uveitis. , 2017, , .		0
160	SAT0616â€¦Ten-year retention rate of infliximab in patients with behçet's disease-related uveitis. , 2018, , .		0
161	THU0299â€¦PATIENT GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN BEHçET'S SYNDROME: A MULTICENTER STUDY. , 2019, , .		0
162	SAT0380â€¦FIBROMYALGIA IS THE STRONGEST NEGATIVE PREDICTOR FOR THE ACHIEVEMENT OF EITHER REMISSION AND MINIMAL DISEASE ACTIVITY IN NAIVE PSORIATIC ARTHRITIS PATIENTS STARTING BIOLOGIC DRUGS. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
163	AB0245â€¦...PREDICTORS OF BIOLOGIC THERAPY DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS AFTER REMISSION ACHIEVEMENT: A MONOCENTRIC OBSERVATIONAL STUDY FROM BIOLOGIC APULIAN REGISTRY (BIOPURE). , 2019, , .		0
164	SAT0240â€¦...DEVELOPMENT AND PRELIMINARY VALIDATION OF THE BEHÄ†ETÄ€™S SYNDROME OVERALL DAMAGE INDEX (BODI). , 2019, , .		0
165	AB0600â€¦...APREMILAST EFFECTIVENESS IN REFRACTORY ORAL AND GENITAL ULCERS OF BEHÄ†ETÄ€™S DISEASE: DATA FROM REAL LIFE SETTINGS. , 2019, , .		0
166	AB0640â€¦...SURVIVAL AND MORTALITY PREDICTORS IN SYSTEMIC SCLEROSIS: RESULTS FROM A MONOCENTRIC ITALIAN COHORT. , 2019, , .		0
167	FRI0070â€¦...SHORT-TERM INFLAMMATORY AND LIPIDS CHANGES IN RHEUMATOID ARTHRITIS PATIENTS INFLUENCE CARDIOVASCULAR RISK ALGORITHMS: A MONOCENTRIC RETROSPECTIVE STUDY. , 2019, , .		0
168	Response to: â€œResponse to: â€œInfluence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patientsâ€œ by Fornaro et alâ€™™ by Agca et al. Annals of the Rheumatic Diseases, 2020, 79, e106-e106.	0.5	0
169	Splenic Infarction as Only Manifestation of Antiphospholipid Syndrome in a Patient With Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2020, 26, e102-e102.	0.5	0
170	AB0380â€¦...MACHINE LEARNING CAN PREDICT GIANT CELL ARTERITIS RELAPSE AFTER GLUCOCORTICOID TAPERING. Annals of the Rheumatic Diseases, 2021, 80, 1217-1217.	0.5	0
171	POS0631â€¦...COMPARATIVE EFFICACY OF COMBINATION THERAPY WITH BIOLOGIC OR TARGET SYNTHETIC DRUGS FOR RHEUMATOID ARTHRITIS: A BAYESIAN NETWORK META-ANALYSIS. Annals of the Rheumatic Diseases, 2021, 80, 553.2-554.	0.5	0
172	Histopathological characteristics of synovitis in Familial Mediterranean Fever (FMF). Joint Bone Spine, 2022, 89, 105259.	0.8	0
173	THU0153â€¦...The effect of 5-years b-dmards treatment on different 10-years cardiovascular risk scores applied in rheumatoid arthritis patients. , 2018, , .		0
174	AB0836â€¦...Drug retention rate of the first tn timer in radiographic and non radiographic axial spondyloarthritis: data from a multicenter study. , 2018, , .		0
175	AB0369â€¦...Adult-onset stillâ€™™s disease treatment predictors at 1-year follow-up in a single rheumatologic centre experience. , 2018, , .		0
176	SAT0307â€¦...Impact of the modified rheumatic disease comorbidity index(MRDCI) on drug survival of first line anti-tnf drugs in patents affected with psoriatic arthritis in real life setting. , 2018, , .		0
177	OP0129â€¦...Drug survival on anti-tnf-alpha in psoriatic arthritis patients with axial involvement and analysis of predictors. , 2018, , .		0
178	THU0168â€¦...Relationships between body fat composition assessed with bioelectrical impedance analysis, serum adipokines and disease activity in patients with rheumatoid arthritis. , 2018, , .		0
179	SAT0605â€¦...The presence of uveitis predicts the response to the interleukin (IL)-1 inhibitors anakinra and canakinumab in behÄ†etÄ€™s disease. , 2018, , .		0
180	FRI0075â€¦...Risk of hepatitis b infection reactivation in rheumatic diseases patients treated with anti-cd20 therapy. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
181	AB0844â€¦SERUM sCD40L LEVEL CAN PREDICT SHORT-TERM CLINICAL OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS ON TREATMENT WITH APREMILAST.. Annals of the Rheumatic Diseases, 2020, 79, 1728-1729.	0.5	0
182	Efficacy of monoclonal anti-tumour necrosis factor-Î± antibodies in uveitic macular oedema. Clinical and Experimental Rheumatology, 2020, 38, 621-625.	0.4	0
183	Reply to Praprotnik and Tomsic and erratum corrige. Clinical and Experimental Rheumatology, 2020, 38, 1034.	0.4	0
184	Safety and effectiveness in switching from reference to biosimilar rituximab in rheumatoid arthritis patients: real world experience from a single Italian rheumatology centre. Clinical and Experimental Rheumatology, 2021, 39, 1147-1148.	0.4	0
185	Splenic Infarction as Only Manifestation of Antiphospholipid Syndrome in a Patient With Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2018, 26, 1.	0.5	0
186	Retention rate of IL-1 inhibitors in Schnitzler's syndrome.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0